Melanie Kleinschek, DVM, PhD

Dr. Melanie Kleinschek is Chief Scientific Officer of TRexBio and brings 20 years of drug discovery experience in translational immunology spanning target identification through early clinical development. She has a proven track record for developing research insights into innovative therapeutic approaches for autoimmune and inflammatory diseases.

Prior to joining TRexBio, Dr. Kleinschek was VP of Science and Innovation Strategy at Theravance, where she led disease area and indication strategy across the inflammation and fibrosis franchises. Before that, as VP of Biology & Pharmacology, she led a large research team to support all preclinical and translational biology activities for Theravance’s respiratory, GI, skin and ocular inflammation programs helping to bring multiple drug candidates to the clinic. Earlier in her career, Dr. Kleinschek held roles of increasing responsibility in the respiratory & immunology franchise at Merck and Schering-Plough with a target identification and drug discovery focus on mucosal immunology and immunoregulation.

Dr. Kleinschek received her PhD in immunology at Leipzig University and her DVM at the Justus Liebig University, Giessen in Germany. Her postdoctoral research at DNAX in the field of cytokine biology in inflammatory diseases founded her career in drug discovery.